Last $14.34 USD
Change Today -0.78 / -5.16%
Volume 19.9K
ESPR On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 8:10 PM 07/24/14 All times are local (Market data is delayed by at least 15 minutes).

esperion therapeutics inc (ESPR) Snapshot

Open
$14.93
Previous Close
$15.12
Day High
$15.05
Day Low
$14.29
52 Week High
08/13/13 - $20.10
52 Week Low
11/27/13 - $10.90
Market Cap
221.4M
Average Volume 10 Days
20.1K
EPS TTM
$-4.32
Shares Outstanding
15.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ESPERION THERAPEUTICS INC (ESPR)

Related News

No related news articles were found.

esperion therapeutics inc (ESPR) Related Businessweek News

No Related Businessweek News Found

esperion therapeutics inc (ESPR) Details

Esperion Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of oral, low-density lipoprotein cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. Its products include ETC-1002, an oral molecule therapy that is in Phase IIb clinical trials to treat lipid and carbohydrate metabolic pathways; ESP41091, which is in pre-clinical trials for type 2 diabetes and obesity treatment; and 4WF, a synthetic apoA-I therapy that is in pre-clinical trials for treating patients with acute coronary syndrome. The company is headquartered in Plymouth, Michigan.

16 Employees
Last Reported Date: 03/13/14

esperion therapeutics inc (ESPR) Top Compensated Officers

Chief Executive Officer, President, Principal...
Total Annual Compensation: $400.0K
Senior Advisor to Chief Executive Officer
Total Annual Compensation: $335.0K
Executive Chairman and Chief Scientific Offic...
Total Annual Compensation: $375.0K
Compensation as of Fiscal Year 2013.

esperion therapeutics inc (ESPR) Key Developments

Esperion Therapeutics Enters into Loan and Security Agreement Up to $20.0 Million with Oxford Finance LLC

On June 30, 2014, Esperion Therapeutics, Inc. entered into a loan and security agreement with Oxford Finance LLC pursuant to which the Lender has agreed to lend the company up to $20.0 million. Upon entering into the Loan and Security Agreement, the company borrowed $5.0 million from the Lender (Term Loan A). Under the terms of the Loan and Security Agreement, the company may, at its sole discretion, borrow from the Lender up to an additional $15.0 million, at any time on or before March 31, 2015, in each case subject to the company's satisfaction of specified conditions precedent described in the Loan and Security Agreement, including certain clinical study milestones. The proceeds from Term Loan A and any future loans under the Loan and Security Agreement may be used to satisfy the company's future working capital needs, potentially including the development of its clinical and preclinical product candidates. The company's obligations under the Loan and Security Agreement are secured by a first priority security interest in substantially all of the assets of the company, other than intellectual property. The company has agreed not to pledge or otherwise encumber its intellectual property assets, other than through grants of certain permitted non-exclusive or exclusive licenses or other conveyances of its intellectual property. The company is required to pay interest on Term Loan A on a monthly basis through and including August 1, 2015, if Term Loan B has not been borrowed by March 31, 2015, and through and including February 1, 2016, if Term Loan B has been borrowed by March 31, 2015. After August 1, 2015, or February 1, 2016, as applicable, the company will be required to make payments of outstanding principal and interest on Term Loan A in equal monthly installments through and including August 1, 2018. Payments due under Term Loan B, if borrowed, are interest only, payable monthly, in arrears, through and including February 1, 2016, followed by 30 payments of principal and interest which are payable monthly, in arrears. The interest rate on the Term Loans is fixed at the greater of 6.40% or the sum of the three month U.S. Dollar LIBOR rate three business days prior to the funding of such Term Loan, plus and 6.17%.

Esperion Therapeutics, Inc. Appoints Gilbert S. Omenn to Board of Directors

Esperion Therapeutics, Inc. announced the appointment of Gilbert S. Omenn, M.D., Ph.D. as a Class II Director, with a term of office expiring in 2015 at the annual meeting of stockholders. Dr. Omenn is Professor of Computational Medicine & Bioinformatics, Internal Medicine, Human Genetics and Public Health, and Director of the Center for Computational Medicine and Bioinformatics at the University of Michigan. He serves on the Scientific Management Review Board of the National Institute of Health (NIH) and the Community Preventive Services Task Force of the Centers for Disease Control and Prevention (CDC). Previously, Dr. Omenn served as Chief Executive Officer of the University of Michigan Health System and Executive Vice President of the University of Michigan for Medical Affairs.

Esperion Therapeutics, Inc. Presents at The Michigan Growth Capital Symposium, Jun-17-2014 02:30 PM

Esperion Therapeutics, Inc. Presents at The Michigan Growth Capital Symposium, Jun-17-2014 02:30 PM. Venue: Marriott Resort at Eagle Crest, 1275 S. Huron Street, Ypsilanti, MI 48197, United States. Speakers: Timothy M. Mayleben, Chief Executive Officer, President, Principal Financial Officer and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ESPR:US $14.34 USD -0.78

ESPR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ESPR.
View Industry Companies
 

Industry Analysis

ESPR

Industry Average

Valuation ESPR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ESPERION THERAPEUTICS INC, please visit www.esperion.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.